UniProtKB/Swiss-Prot P07355: Variant p.Val98Leu

Annexin A2
Gene: ANXA2
Feedback?

Variant information Variant position:

98 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Type of variant:

LB/B The variants are classified into three categories: LP/P, LB/B and US.

LP/P: likely pathogenic or pathogenic.
LB/B: likely benign or benign.
US: uncertain significance

Residue change:

From Valine (V) to Leucine (L) at position 98 (V98L, p.Val98Leu). Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.
Physico-chemical properties:

Similar physico-chemical property. Both residues are medium size and hydrophobic. The physico-chemical property of the reference and variant residues and the change implicated.
BLOSUM score:

1 The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:

Lowest score: -4 (low probability of substitution).
Highest score: 11 (high probability of substitution).

More information can be found on the following page
Variant description:

Does not affect interaction with PCSK9. Any additional useful information about the variant.
Other resources:

Links to websites of interest for the variant.

Variant rs17845226 [ dbSNP | Ensembl ]

Sequence information Variant position:

98 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Protein sequence length:

339 The length of the canonical sequence.
Location on the sequence:

RTKKELASALKSALSGHLET V ILGLLKTPAQYDASELKASM The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.
Residue conservation:

The multiple alignment of the region surrounding the variant against various orthologous sequences.

Human                         RTKKELASALKSALSGHLETVILGLLKTPAQYDASELKASM

                              RTKKELASALKSALSGHLETVILGLLKTPAQYDASELKASM

Mouse                         RTKKELPSALKSALSGHLETVILGLLKTPAQYDASELKASM

Rat                           RTKKELPSAMKSALSGHLETVMLGLLKTPAQYDASELKASM

Pig                           RTKKELASALKSALSGHLETVILGLLKTPAQYDASELKASM

Bovine                        RTKKELASALKSALSGHLETVILGLLKTPAQYDASELKASM

Sheep                         RTKKELASALKSALSGHLETVILGLLKTPAQYDASELKASM

Chicken                       RTKKELSAALKSALSGHLEAVILGLLKTPSQYDASELKAAM

Sequence annotation in neighborhood:

The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:

Type: the type of sequence feature.
Positions: endpoints of the sequence feature.
Description: contains additional information about the feature.

Type	Positions	Description
Chain	2 – 339	Annexin A2
Repeat	33 – 104	Annexin 1
Mutagenesis	88 – 88	K -> A. Strongly decreases interaction with PCSK9; when associated with 77-A--A-80.
Helix	93 – 103

Literature citations
The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).
The MGC Project Team;
Genome Res. 14:2121-2127(2004)
Cited for: NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1); VARIANT LEU-98; Annexin A2 is a natural extrahepatic inhibitor of the PCSK9-induced LDL receptor degradation.
Seidah N.G.; Poirier S.; Denis M.; Parker R.; Miao B.; Mapelli C.; Prat A.; Wassef H.; Davignon J.; Hajjar K.A.; Mayer G.;
PLoS ONE 7:E41865-E41865(2012)
Cited for: FUNCTION; VARIANT LEU-98; CHARACTERIZATION OF VARIANT LEU-98; MUTAGENESIS OF 28-LYS--GLU-36; 37-ARG--LYS-47; 77-ARG--LYS-80 AND 77-ARG--LYS-81;

Disclaimer: Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.